Skip to content

Effect of Intravenous Lidocaine on Hemodynamic Responses to Tracheal Intubation during Remimazolam-Based Anesthetic Induction with Remifentanil Target-Controlled Infusion

Effect of Intravenous Lidocaine on Hemodynamic Responses to Tracheal Intubation during Remimazolam Induction with Remifentanil Target-Controlled Infusion: A Randomized, Placebo-Controlled Trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CRIS
Registry ID
KCT0011685
Enrollment
80
Registered
2026-03-05
Start date
2026-03-12
Completion date
Unknown
Last updated
2026-03-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Drug : 1. Anesthesia induction will be performed using remifentanil and remimazolam, with patients receiving either lidocaine or placebo (normal saline). 2. Study drug (lidocaine/placebo): After conf

Sponsors

Samsung Changwon Medical Center
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Adults aged 18 years or older and younger than 70 years

Exclusion criteria

Exclusion criteria: Anticipated difficult airway BMI = 40 kg/m² Severe cardiovascular disease Conduction abnormalities or bradycardia (heart rate = 50/min) History of hypersensitivity to study medications History of dextran hypersensitivity Cognitive impairment Any other condition deemed inappropriate for participation by the investigator

Design outcomes

Primary

MeasureTime frame
?MAP: Change in mean arterial pressure at 1 minute after successful intubation (T+1) compared with baseline.

Secondary

MeasureTime frame
?MAPbaseline?T+2: Change in mean arterial pressure at 2 minutes after successful intubation (T+2) compared with baseline.;?HRbaseline?T+1, ?HRbaseline?T+2:Changes in heart rate at 1 and 2 minutes after successful intubation compared with baseline.

Countries

Korea, Republic of

Contacts

Public ContactMoon Ok Lee

Masan Samsung Medical Center

lmo602@hanmail.net+82-55-233-6049

Outcome results

None listed

Source: CRIS (via WHO ICTRP) · Data processed: Mar 14, 2026